1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Compounding Bill In Senate Adds Office Use Provisions

 
• By Derrick Gingery

New version of compounding bill would allow compounders to produce limited supplies for office use, but schedule for Senate floor action remains to be seen.

An updated Senate compounding bill makes specific provisions for office use of the medications, but limits it to a fraction of a compounder’s overall production.

The new language places the limit on the number of compounded drugs dispensed based on practitioner orders. It also restricts office use production to traditional compounders, which are generally those...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.

US FDA Makary’s Pharma CEO Tour Goes Against Transparency Rhetoric

 
• By Sarah Karlin-Smith

FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.

US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’

 
• By Francesca Bruce

Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.